Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

1,009 results

• First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221: Complete Statistical AnalysisIndependent statistical analysis of First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 29NCT02675465
• FirstStep2Health Intervention: Complete Statistical AnalysisIndependent statistical analysis of FirstStep2Health Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04164277).Phase NAResults postedn = 95NCT04164277
• FITESTIndependent statistical analysis of Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 60NCT02722499
• Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896): Complete Statistical AnalysisIndependent statistical analysis of Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 306NCT01190254
• FLAXPADIndependent statistical analysis of Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2/3Results postedn = 110NCT00781950
• FLOREYIndependent statistical analysis of Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 89NCT02189837
• FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…Phase 3Results postedn = 3,533NCT03819153
• FLOWIndependent statistical analysis of A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 3,533NCT03819153
• FMT ObesityIndependent statistical analysis of Fecal Microbiota Transplantation for the Treatment of Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02741518).Phase 1/2Results postedn = 22NCT02741518
• FOHSIndependent statistical analysis of Efficacy Study Regarding the Beneficial Effects of Omega-3 Fatty Acids on Cardiometabolic Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 12NCT02042274
• FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01688336).Phase 2Results postedn = 9NCT01688336
• FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267): Complete Statistical AnalysisIndependent statistical analysis of FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01065779).Phase NAResults postedn = 880NCT01065779
• FOURIER-OLEAn independent statistical analysis and educational interpretation of FOURIER-OLE, a phase 3 open-label extension study of evolocumab in participants with dyslipidemia.Phase 3Results postedn = 5,035NCT02867813
• FPSIndependent statistical analysis of Effects of Obesity Treatments on Food Preferences and Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01724060).Phase NAResults postedn = 80NCT01724060
• Fracture Risk With Thiazolidinediones: Complete Statistical AnalysisIndependent statistical analysis of Fracture Risk With Thiazolidinediones: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01055223).Phase NAResults postedn = 98,483NCT01055223
• FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…Phase 3Results postedn = 1,900NCT00086450
• FRESHIndependent statistical analysis of FRESH Study (Fitness, Relaxation and Eating to Stay Healthy): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01636258).Phase NAResults postedn = 27NCT01636258
• FRONTIERIndependent statistical analysis of Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 289NCT05085275
• G-Pen™ for Hypoglycemia Rescue in T1D Patients: Complete Statistical AnalysisIndependent statistical analysis of G-Pen™ for Hypoglycemia Rescue in T1D Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02423980).Phase 2Results postedn = 7NCT02423980
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138124).Phase NAResults postedn = 54,202NCT01138124
• Garlic4Independent statistical analysis of Effect of Aged Garlic Extract on Atherosclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534910).Phase 4Results postedn = 65NCT01534910
• Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170870).Phase 2Results postedn = 104NCT02170870
• GATEWAYIndependent statistical analysis of A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 4NCT04537377
• Gemcabene for the Treatment of Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Gemcabene for the Treatment of Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436420).Phase 2Results postedn = 6NCT03436420
• Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 123NCT00733746
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 83NCT01585805
• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 118NCT01064622
• Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).Phase 2Results postedn = 44NCT01459614
• GETGOAL-L-ASIAIndependent statistical analysis of GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA): primary endpoint results, effect…Phase 3Results postedn = 311NCT00866658
• GETGOAL-MONOIndependent statistical analysis of GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 361NCT00688701
• GIANTIndependent statistical analysis of Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control: primary endpoint results, effect estimate with…Phase 4Results postedn = 202NCT01066039
• Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency: Complete Statistical AnalysisIndependent statistical analysis of Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 114NCT00911625
• GLEAMIndependent statistical analysis of A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 460NCT04611152
• GLIMPIndependent statistical analysis of Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 7NCT05254418
• GLITTER 2Independent statistical analysis of Gan & Lee Insulin Glargine Target Type (2) Evaluating Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03371108).Phase 3Results postedn = 567NCT03371108
• Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 1NCT04079881
• Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong – Darmstadt): Complete Statistical AnalysisIndependent statistical analysis of Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03566810).Phase 1Results postedn = 54NCT03566810
• Glucose Regulation in Acute Stroke Patients (GRASP) Study: Complete Statistical AnalysisIndependent statistical analysis of Glucose Regulation in Acute Stroke Patients (GRASP) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00282867).Phase 2Results postedn = 74NCT00282867
• Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.: Complete Statistical AnalysisIndependent statistical analysis of Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 96NCT06546657
• GlulipidIndependent statistical analysis of Glucose and Lipid Metabolism on Antipsychotic Medication: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515723).Phase NAResults postedn = 96NCT00515723
• GLUMIT-DGIndependent statistical analysis of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01030341).Phase NAResults postedn = 45NCT01030341
• Glutathione Metabolism in Adolescents With Type 1 Diabetes – Study A: Complete Statistical AnalysisIndependent statistical analysis of Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 10NCT00858897
• Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2/3Results postedn = 631NCT00663260
• GRAVITYIndependent statistical analysis of 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 1,743NCT00525824
• Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism: Complete Statistical AnalysisIndependent statistical analysis of Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00206375).Phase 4Results postedn = 16NCT00206375
• Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: Complete Statistical AnalysisIndependent statistical analysis of Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 77NCT00130286
• Growth-TBIIndependent statistical analysis of Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00766038).Phase 2Results postedn = 63NCT00766038
• GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 31NCT03161379
• H42/H4UIndependent statistical analysis of Pragmatic Randomized Clinical Trial to Limit Weight Gain in Pregnancy and Prevent Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 534NCT04724330
• HABITSIndependent statistical analysis of Healthy Homes, Healthy Habits: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03433456).Phase NAResults postedn = 296NCT03433456

← All therapeutic areas